GLP-1 medications, including the oral semaglutide pill, are generally well-tolerated by many patients
By protecting the optic nerve, semaglutide could, in theory, help slow down the progression of glaucoma
Efficient digestion supports more consistent signaling, while sluggish digestion can disrupt this process
This effect is often temporary, and over time, the appetite may return to normal
News provided by Eli Lilly and Company May 13, 2022, 17:54 ET Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials While not indicated for weight loss, Mounjaro led to significantly greater weight reductions versus comparators in a key secondary endpoint Mounjaro represents the first new class of diabetes medicines introduced in nearly a decade and is expected to be available in the U.S